Project Grant HT94252510166
Award Date
9/1/25
Completion Date
8/31/28
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Awardee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. (UYLKBRENAPG5)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Westlake, MD 20817, USA
Similar Awards
This federal Project Grant award of $2,028,000.00, awarded on April 1, 2025 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research aimed at identifying epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The award was granted to the Icahn School of Medicine at Mount Sinai, a prominent academic medical center and research institution in New York City. Through this...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
The Defense Health Agency awarded a $1,036,233 Project Grant to the Fred Hutchinson Cancer Research Center under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from July 2021 through June 2024 to develop more precise molecular classification and targeted treatment of metastatic castration-resistant prostate cancer (MCRPC) through multi-omic analysis of circulating tumor DNA (ctDNA). By leveraging ctDNA analysis, the research aims to transform...
The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
The federal Project Grant award of $2,136,000.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is focused on "REVERSIBILITY AND THERAPEUTIC TARGETING OF TREATMENT- EMERGENT NEUROENDOCRINE PROSTATE CANCER" and will be performed by the Dana-Farber Cancer Institute, Inc. (Dfci) located in Boston, MA. The grant supports advanced biomedical research aimed at transforming healthcare for military service members,...
This federal Project Grant award of $1,235,845.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports a research project led by the University of Illinois in Chicago. The project aims to leverage data science methods to deliver individualized treatment effects in metastatic hormone sensitive prostate cancer. The award period runs from August 15, 2025 to August 14, 2028. The Military Medical Research and Development program funds...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The federal Project Grant award of $161,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by Duke University to investigate breast cancer brain metastases. The research aims to integrate immunogenomic and phenotypic vulnerabilities to improve outcomes for this challenging condition. The award period runs from April 1, 2025 to March 31, 2026. This grant is part of the Defense Health Agency's strategic...
This federal Project Grant award, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research at the University of Kentucky Research Foundation focused on "Targeting MNK/GRP78 Pathway to Disrupt Proteostasis Rewiring in Castration-Resistant Prostate Cancer". The $1,602,137 award, spanning from April 2025 to April 2028, aims to investigate innovative medical solutions for military personnel and the broader...
This federal Project Grant award for $465,935.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding research conducted by the University of Wisconsin - Madison to combine PSMA and BRD4 disruption approaches to overcome resistance in advanced prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical solutions to critical...